Toggle Main Menu Toggle Search

Open Access padlockePrints

A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors

Lookup NU author(s): Professor Ruth Plummer, Rebecca Perrett, Professor Alan Calvert


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Plummer ER, Vidal L, Perrett RH, Shaw H, Pilkington M, Hanwell J, Temple G, Fong P, Amelsberg A, Calvert AH, de Bono J

Publication type: Article

Publication status: Published

Journal: Clinical Cancer Research

Year: 2005

Volume: 11

Issue: 24 Part 2 Supplement S

Pages: 8990S-8990S

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265

Notes: Conference: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics Philadelphia, PA, 14-18 November 2005.